Transfusion in Critical Care — Part 1: Red Blood Cell Transfusion
Evidence-based hemoglobin thresholds for RBC transfusion in the critically ill, landmark trial evidence (TRICC, TRISS, FOCUS, TITRe2, TRICS-III), physiologic triggers, single-unit policy, compatibility testing, and storage considerations.
1. Introduction: The Shift to Restrictive Transfusion
Red blood cell transfusion is one of the most frequently performed therapeutic interventions in the intensive care unit. Historically, a liberal transfusion strategy maintaining hemoglobin above 10 g/dL (the so-called “10/30 rule” — hemoglobin 10 g/dL or hematocrit 30%) was standard practice for decades despite a lack of evidence supporting this threshold.1 Over the past 25 years, a robust body of randomized controlled trial evidence has demonstrated that a restrictive transfusion strategy — transfusing at lower hemoglobin thresholds — is at least as safe as, and in many populations superior to, liberal transfusion.
The major international transfusion medicine and critical care professional societies now uniformly recommend restrictive transfusion thresholds for most patient populations, with specific modifications for certain clinical contexts including acute coronary syndromes, traumatic brain injury, and active hemorrhage.2 3 4
2. Landmark Randomized Controlled Trials
The evidence base for restrictive transfusion is anchored by several pivotal randomized controlled trials spanning general critical care, sepsis, cardiac surgery, hip fracture surgery, gastrointestinal bleeding, and traumatic brain injury. Understanding these trials is essential for applying transfusion thresholds in clinical practice.
2.1 Summary of Landmark Trials
| Trial | Year | Population | N | Restrictive Threshold | Liberal Threshold | Primary Outcome | Key Result |
|---|---|---|---|---|---|---|---|
| TRICC1 | 1999 | General ICU | 838 | Hb < 7 g/dL | Hb < 10 g/dL | 30-day mortality | No difference overall (18.7% vs 23.3%); trend toward lower mortality in restrictive group; significantly lower mortality in restrictive group among patients with APACHE II ≤ 20 and age < 55 |
| TRISS5 | 2014 | Septic shock | 998 | Hb ≤ 7 g/dL | Hb ≤ 9 g/dL | 90-day mortality | No difference (43.0% vs 45.0%); fewer transfusions in restrictive group (median 1 vs 4 units) |
| FOCUS6 | 2011 | Hip fracture (elderly, CVD risk) | 2,016 | Hb < 8 g/dL + symptoms | Hb < 10 g/dL | 60-day mortality or inability to walk | No difference (35.2% vs 34.7%); restrictive strategy non-inferior |
| TITRe27 | 2015 | Cardiac surgery | 2,003 | Hb < 7.5 g/dL | Hb < 9 g/dL | Serious infection or ischemic event (composite) | No significant difference in composite outcome; slightly higher 90-day mortality in restrictive group (4.2% vs 2.6%, p=0.045) — generates equipoise for cardiac surgery |
| TRICS-III8 | 2017 | Cardiac surgery (moderate-to-high risk) | 5,243 | Hb < 7.5 g/dL | Hb < 9.5 g/dL | Composite of death, MI, stroke, new-onset renal failure | Non-inferior (11.4% vs 12.5%); restrictive strategy safe in cardiac surgery |
| MINT9 | 2023 | Acute MI (STEMI and NSTEMI) | 3,504 | Hb < 7 or 8 g/dL | Hb < 10 g/dL | 30-day composite of MI or death | Higher event rate in restrictive group (16.9% vs 14.5%); suggests liberal threshold may be appropriate in acute MI |
| Villanueva et al.10 | 2013 | Acute upper GI bleeding | 921 | Hb < 7 g/dL | Hb < 9 g/dL | 45-day mortality | Significantly lower mortality in restrictive group (5% vs 9%, p=0.02); lower rebleeding rate |
| Robertson et al.11 | 2014 | Traumatic brain injury | 200 | Hb < 7 g/dL | Hb < 10 g/dL | 6-month neurologic outcome (GOS-E) | No significant difference in favorable neurologic outcome; underpowered; some guidelines recommend higher threshold for TBI |
2.2 TRICC Trial — Detailed Review
The Transfusion Requirements in Critical Care (TRICC) trial, published in 1999, was the first major randomized trial to challenge the traditional liberal transfusion paradigm in the ICU.1
Design: Multicenter (25 Canadian ICUs), randomized, controlled trial. Euvolemic critically ill patients with hemoglobin < 9 g/dL within 72 hours of ICU admission were randomized to:
- Restrictive group: Transfusion trigger Hb < 7 g/dL, target Hb 7.0–9.0 g/dL
- Liberal group: Transfusion trigger Hb < 10 g/dL, target Hb 10.0–12.0 g/dL
Results:
- 30-day mortality: 18.7% (restrictive) vs 23.3% (liberal) — not statistically significant for the overall cohort (p = 0.11)
- In-hospital mortality: 22.2% vs 28.1% (p = 0.05)
- In patients with APACHE II scores ≤ 20: 30-day mortality was significantly lower in the restrictive group (8.7% vs 16.1%, p = 0.03)
- In patients aged < 55 years: mortality was significantly lower in the restrictive group (5.7% vs 13.0%, p = 0.02)
- The restrictive strategy resulted in a 54% reduction in RBC units transfused
- No difference in organ dysfunction scores (MODS) between groups
- Cardiac events were similar between groups
Clinical significance: This trial established that a hemoglobin threshold of 7 g/dL is safe for most ICU patients and may be superior to liberal transfusion, particularly in younger and less acutely ill patients. It ended the era of the “10/30 rule.”
2.3 TRISS Trial — Detailed Review
The Transfusion Requirements in Septic Shock (TRISS) trial specifically evaluated transfusion thresholds in patients with septic shock — a population where oxygen delivery optimization had historically been a key resuscitation target.5
Design: Multicenter (32 Scandinavian and Canadian ICUs), randomized, controlled trial. Patients with septic shock and hemoglobin ≤ 9 g/dL were randomized to:
- Restrictive group: Transfusion trigger Hb ≤ 7 g/dL
- Liberal group: Transfusion trigger Hb ≤ 9 g/dL
Results:
- 90-day mortality (primary endpoint): 43.0% (restrictive) vs 45.0% (liberal) — absolute difference -2.0% (95% CI, -9.6 to 5.5; p = 0.44)
- Fewer patients received transfusion in the restrictive group (64.0% vs 98.8%)
- Median units transfused: 1 unit (restrictive) vs 4 units (liberal)
- No difference in ischemic events, use of life support, or 90-day mortality in any pre-specified subgroup
- Rates of adverse events were similar between groups
Clinical significance: Restrictive transfusion (Hb ≤ 7 g/dL) is safe in septic shock and results in significantly fewer transfusions without increased mortality or ischemic events. This trial directly informs ICU practice for one of the most common critical care populations.
2.4 MINT Trial — Acute Myocardial Infarction
The Myocardial Ischemia and Transfusion (MINT) trial, published in 2023, was the largest trial to evaluate transfusion thresholds specifically in patients with acute myocardial infarction and anemia.9
Design: Multicenter (144 sites in the US, Canada, Australia, and France), open-label, randomized trial. Patients with acute MI (STEMI or NSTEMI) and hemoglobin < 10 g/dL were randomized to:
- Restrictive group: Transfusion permitted only if Hb < 7 g/dL or < 8 g/dL with symptoms
- Liberal group: Transfusion to target Hb ≥ 10 g/dL
Results:
- 30-day composite of death or recurrent MI: 16.9% (restrictive) vs 14.5% (liberal)
- The restrictive strategy did not meet non-inferiority criteria
- Trend toward benefit with liberal transfusion in acute MI patients
Clinical significance: This trial suggests that patients with acute MI may benefit from a more liberal transfusion threshold (Hb < 8–10 g/dL), making this the primary population where higher transfusion thresholds remain appropriate.
3. Recommended Hemoglobin Thresholds by Clinical Scenario
The following table synthesizes current evidence-based recommendations from the major transfusion medicine and critical care professional societies.2 3 4 12
3.1 RBC Transfusion Threshold Summary Table
| Clinical Scenario | Transfusion Trigger (Hb) | Strength of Recommendation | Key Evidence |
|---|---|---|---|
| General ICU (hemodynamically stable) | ≤ 7 g/dL | Strong recommendation, high-quality evidence | TRICC trial1 |
| Sepsis / Septic shock | ≤ 7 g/dL | Strong recommendation, moderate-quality evidence | TRISS trial5 |
| Cardiac surgery (postoperative) | ≤ 7.5 g/dL | Strong recommendation, high-quality evidence | TRICS-III8; TITRe27 supports equipoise |
| Acute coronary syndrome / STEMI / NSTEMI | ≤ 8 g/dL (consider up to 10 g/dL) | Conditional recommendation, moderate-quality evidence | MINT trial9; ACC/AHA guidelines |
| Stable cardiovascular disease (non-ACS) | ≤ 8 g/dL | Strong recommendation, moderate-quality evidence | FOCUS trial6 |
| Acute upper GI bleeding (hemodynamically stable) | ≤ 7 g/dL | Strong recommendation, moderate-quality evidence | Villanueva et al.10 |
| Acute hemorrhagic shock (massive bleeding) | Clinical judgment; do not wait for Hb threshold | N/A — resuscitate with MTP | See Part 3 |
| Traumatic brain injury | ≤ 7 g/dL (some guidelines suggest ≤ 10 g/dL) | Conditional recommendation, low-quality evidence | Robertson et al.11; neurocritical care guidelines |
| ECMO | ≤ 7 g/dL | Conditional recommendation, very low evidence | ELSO guidelines; extrapolated from general ICU data |
| Obstetric patients (non-hemorrhagic) | ≤ 7 g/dL | Conditional recommendation, low-quality evidence | Extrapolated; no large RCTs |
| Chronic transfusion-dependent anemia | Per disease-specific guidelines | Varies | Thalassemia, MDS, sickle cell disease |
| Preoperative (elective surgery) | ≤ 7–8 g/dL | Conditional recommendation, moderate-quality evidence | Society consensus2 |
3.2 Key Principles
- The default ICU transfusion trigger is Hb ≤ 7 g/dL for hemodynamically stable patients without acute coronary syndromes.1 2 5
- Acute coronary syndromes are the primary exception — a threshold of Hb ≤ 8 g/dL (and possibly up to 10 g/dL) is supported by the MINT trial.9
- Active hemorrhage with hemodynamic instability should not be managed by hemoglobin thresholds alone — clinical judgment and massive transfusion protocols take precedence.
- Transfuse one unit at a time and reassess after each unit before ordering additional units (single-unit transfusion policy).2
- Hemoglobin alone should not be the sole decision-making parameter — integrate physiologic triggers (see Section 4).
4. Physiologic Transfusion Triggers
While hemoglobin thresholds provide a standardized framework, clinical decision-making should also incorporate physiologic indicators of inadequate oxygen delivery, particularly when hemoglobin values are between 7 and 10 g/dL or when the clinical picture is uncertain.3 12
4.1 Physiologic Indicators of Inadequate Oxygen Delivery
| Parameter | Suggests Transfusion May Be Beneficial | Notes |
|---|---|---|
| Serum lactate | Rising or persistently elevated (> 2 mmol/L) despite adequate volume resuscitation | Indicates tissue hypoperfusion; must distinguish from other causes of hyperlactatemia (epinephrine, liver dysfunction, metformin) |
| Central venous O₂ saturation (ScvO₂) | < 70% | Reflects the balance between oxygen delivery and consumption; values < 70% suggest increased oxygen extraction |
| Mixed venous O₂ saturation (SvO₂) | < 65% | Requires pulmonary artery catheter; more accurate than ScvO₂ but less commonly available |
| Oxygen extraction ratio (O₂ER) | > 40% | Calculated: (SaO₂ - SvO₂) / SaO₂; indicates oxygen delivery is approaching the critical DO₂ |
| Heart rate / tachycardia | New or worsening tachycardia out of proportion to clinical condition | Non-specific; may reflect hypovolemia, pain, fever, or other causes |
| Hypotension | New hypotension not explained by other causes | Must exclude hypovolemia, sepsis, cardiac dysfunction |
| Signs of myocardial ischemia | New ST changes, chest pain, troponin rise | Especially relevant in patients with cardiovascular disease; supports higher transfusion threshold |
| Symptomatic anemia | Dyspnea at rest, presyncope, severe fatigue | Clinical judgment; more relevant in subacute/chronic anemia |
4.2 Integrating Hemoglobin and Physiologic Triggers
The decision to transfuse should integrate the hemoglobin level, clinical trajectory, and physiologic indicators:
- Hb ≤ 7 g/dL: Transfuse (in most populations) regardless of symptoms
- Hb 7–8 g/dL: Transfuse if physiologic triggers present (elevated lactate, low ScvO₂, ischemic signs) or in ACS/cardiovascular disease patients
- Hb 8–10 g/dL: Transfuse only in specific circumstances — active ACS with ischemic signs, active hemorrhage, or profound physiologic compromise
- Hb > 10 g/dL: Transfusion is almost never indicated; very rare exceptions include sickle cell disease (exchange transfusion targets) and specific chronic transfusion protocols
5. Single-Unit Transfusion Policy
5.1 Rationale
Multiple professional societies recommend a “transfuse one, reassess” approach: administer one unit of packed red blood cells (pRBC), then reassess the patient’s hemoglobin level and clinical status before ordering additional units.2 3 This policy:
- Reduces unnecessary transfusions by 20–30% in audited implementations
- Minimizes exposure to transfusion-related adverse events
- Avoids transfusion-associated circulatory overload (TACO), particularly in elderly and cardiac patients
- Aligns with patient blood management principles
5.2 Exceptions to Single-Unit Policy
- Active hemorrhage: Patients with ongoing hemorrhage and hemodynamic instability should receive blood products per massive transfusion protocol (see Part 3)
- Profound anemia with instability: Hb < 5 g/dL with hemodynamic compromise may warrant initial 2-unit order
- Massive transfusion protocol activation: Components are delivered in fixed-ratio packs
5.3 Expected Hemoglobin Rise Per Unit
| Patient Characteristic | Expected Hb Rise per Unit pRBC | Notes |
|---|---|---|
| Average adult (70 kg) | 1.0 g/dL | Equivalent to ~3% rise in hematocrit |
| Smaller adult (< 50 kg) | 1.2–1.5 g/dL | Greater proportional effect |
| Larger adult (> 100 kg) | 0.5–0.7 g/dL | Smaller proportional effect |
| Active bleeding | Unpredictable | Hemoglobin may not rise despite transfusion; reassess clinically |
| Volume-overloaded patient | May be higher than expected | Hemoconcentration effect |
A post-transfusion hemoglobin should be checked 1–2 hours after completion of the transfusion (assuming no active bleeding) to guide further transfusion decisions.
6. Ordering, Compatibility, and Crossmatch
6.1 ABO and Rh Blood Group System
| Blood Type | RBC Antigens | Plasma Antibodies | RBC Compatibility (Can Receive From) | Plasma Compatibility (Can Receive From) |
|---|---|---|---|---|
| O-negative | None | Anti-A, Anti-B | O-neg only | O, A, B, AB |
| O-positive | D (Rh) | Anti-A, Anti-B | O-neg, O-pos | O, A, B, AB |
| A-negative | A | Anti-B | O-neg, A-neg | A, AB |
| A-positive | A, D | Anti-B | O-neg, O-pos, A-neg, A-pos | A, AB |
| B-negative | B | Anti-A | O-neg, B-neg | B, AB |
| B-positive | B, D | Anti-A | O-neg, O-pos, B-neg, B-pos | B, AB |
| AB-negative | A, B | None | O-neg, A-neg, B-neg, AB-neg | AB |
| AB-positive | A, B, D | None | Universal recipient (all types) | AB |
Emergency uncrossmatched blood:
- O-negative pRBCs are the universal donor for RBC transfusion
- Use O-negative for females of childbearing potential (to avoid Rh sensitization)
- O-positive may be used for males and females beyond childbearing age in emergencies
- Switch to type-specific blood as soon as a type and screen is available (typically 15–30 minutes)
6.2 Pre-Transfusion Testing
| Test | Purpose | Time Required | When Used |
|---|---|---|---|
| Type and screen (T&S) | Determines ABO/Rh type; screens for unexpected antibodies | 30–45 minutes | Routine pre-transfusion; valid for up to 72 hours if no recent transfusion or pregnancy |
| Crossmatch (electronic) | Computer-verified ABO compatibility | 5–10 minutes | Used when antibody screen is negative and patient has no history of clinically significant antibodies |
| Crossmatch (serologic/immediate spin) | In vitro verification of ABO compatibility | 15–20 minutes | When electronic crossmatch criteria are not met |
| Full crossmatch (antiglobulin/indirect Coombs) | Detects IgG antibodies; confirms compatibility | 45–60 minutes | Required when antibody screen is positive or patient has known alloantibodies |
| Antibody identification | Identifies specific alloantibody | 1–4 hours (may take longer) | When antibody screen is positive; critical for providing antigen-negative units |
6.3 Maximum Surgical Blood Order Schedule (MSBOS)
The MSBOS is an institution-specific guideline that standardizes blood ordering for surgical procedures based on historical transfusion rates. The goal is to ensure that blood is available when needed while minimizing unnecessary crossmatching and wastage. Key principles:
- Procedures with < 10% historical transfusion rate: Type and screen only (no crossmatch)
- Procedures with > 10% transfusion rate: Type and crossmatch the expected number of units
- Emergency surgery without a type and screen: Issue uncrossmatched O-negative (or O-positive) blood
7. RBC Product Characteristics and Storage
7.1 Packed Red Blood Cell (pRBC) Product Specifications
| Parameter | Standard pRBC Unit |
|---|---|
| Volume | 250–350 mL (includes additive solution) |
| Hematocrit | 55–80% |
| Storage solution | CPDA-1 (35-day shelf life) or additive solutions — AS-1 (Adsol), AS-3 (Nutricel), AS-5 (Optisol) (42-day shelf life) |
| Storage temperature | 1–6°C |
| Infusion time | Must complete within 4 hours of leaving controlled storage; typically infuse over 1.5–2 hours per unit in stable patients |
| Leukoreduction | Pre-storage leukoreduction is universal in most countries; reduces FNHTR, CMV transmission, and HLA alloimmunization |
7.2 Age of Blood — Storage Lesion
The “storage lesion” refers to progressive biochemical and structural changes in stored RBCs:13
- Decreased 2,3-DPG (impaired oxygen offloading; regenerated within 24 hours after transfusion)
- Decreased ATP
- Increased potassium (hyperkalemia risk, especially with rapid transfusion or renal failure)
- Decreased nitric oxide availability
- Increased free hemoglobin and microparticles
- Morphologic changes (echinocytes, spherocytes)
Clinical relevance of blood age:
The ABLE trial (2015, N = 2,430 ICU patients) and the INFORM trial (2017, N = 31,497 hospitalized patients) both demonstrated no clinical difference between fresh (mean storage 6.1 days) and standard-issue (mean storage 22 days) RBCs in terms of 90-day mortality or other clinical outcomes.13 14 Current guidelines do not recommend preferential use of fresh blood; standard blood bank practice (oldest units first, “first in, first out”) is appropriate.
7.3 Special RBC Product Modifications
| Product | Indication | Mechanism |
|---|---|---|
| Leukoreduced | Universal (pre-storage leukoreduction standard in most countries) | Removes > 99.9% of donor WBCs; reduces FNHTR, CMV transmission, HLA alloimmunization |
| Irradiated | Immunocompromised patients at risk for transfusion-associated graft-versus-host disease (TA-GVHD): HCT/BMT recipients, congenital T-cell immunodeficiency, HLA-matched or directed-donor products, intrauterine transfusion, neonatal exchange transfusion | Gamma irradiation (25 Gy) or X-ray prevents donor lymphocyte proliferation; reduces shelf life to 28 days from irradiation |
| Washed | Patients with severe allergic or anaphylactic reactions to plasma proteins; IgA-deficient patients with anti-IgA antibodies | Removes > 99% of plasma proteins; reduces shelf life to 24 hours after washing |
| Volume-reduced | Neonatal or pediatric patients; patients who cannot tolerate full-volume transfusion | Removes excess additive solution/plasma; reduces shelf life to 24 hours |
| Antigen-negative | Patients with identified clinically significant alloantibodies; sickle cell disease (phenotype-matched) | Blood bank identifies units lacking the target antigen(s); may require extended phenotyping or genotyping |
| CMV-seronegative | Historically used for CMV-negative immunocompromised patients; now largely replaced by leukoreduction | Donors tested and confirmed CMV-seronegative; some institutions still require for CMV-negative HCT recipients and pregnant women |
8. Risks and Benefits of RBC Transfusion
8.1 Benefits
- Increases oxygen-carrying capacity and oxygen delivery (DO₂)
- Improves tissue oxygenation when hemoglobin is below the critical DO₂ threshold
- Replaces acute blood loss
- May improve hemodynamic stability in hemorrhagic shock (in combination with volume resuscitation)
8.2 Known Risks
| Risk Category | Examples | Approximate Incidence |
|---|---|---|
| Immunologic | Febrile non-hemolytic reaction (FNHTR) | 1–3% (with leukoreduction: < 0.5%) |
| Allergic reaction (urticaria) | 1–3% | |
| Acute hemolytic reaction (ABO incompatibility) | 1:38,000 to 1:70,000 | |
| Delayed hemolytic reaction | 1:2,500 to 1:11,000 | |
| Anaphylaxis | 1:20,000 to 1:50,000 | |
| TRALI | 1:5,000 to 1:12,000 (decreasing with mitigation strategies) | |
| Alloimmunization (RBC antigens) | 2–6% per transfusion episode | |
| TA-GVHD | Rare (< 1:500,000 with irradiated products) | |
| Non-immunologic | TACO | 1:100 to 1:700 (most common serious reaction) |
| Bacterial contamination (RBCs) | 1:250,000 | |
| Iron overload (chronic transfusion) | Depends on cumulative exposure | |
| Infectious | HIV | < 1:2,000,000 |
| Hepatitis C | < 1:2,000,000 | |
| Hepatitis B | 1:300,000 to 1:1,000,000 | |
| Bacterial sepsis from contaminated unit | 1:250,000 (RBCs); 1:75,000 (platelets) |
8.3 Transfusion-Related Immunomodulation (TRIM)
Allogeneic RBC transfusion is associated with immunomodulatory effects, including:15
- Increased risk of healthcare-associated infections (an association observed in multiple observational studies)
- Possible increased cancer recurrence (controversial; observational data only)
- Increased mortality in critically ill patients when transfused above restrictive thresholds
These associations reinforce the importance of restrictive transfusion practices and single-unit policies.
References
Hébert PC, Wells G, Blajchman MA, et al. “A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care.” N Engl J Med. 1999;340(6):409-417. DOI: 10.1056/NEJM199902113400601 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Carson JL, Guyatt G, Heddle NM, et al. “Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.” JAMA. 2016;316(19):2025-2035. DOI: 10.1001/jama.2016.9185 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Mueller MM, Van Remoortel H, Meybohm P, et al. “Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference.” JAMA. 2019;321(10):983-997. DOI: 10.1001/jama.2019.0554 ↩︎ ↩︎ ↩︎ ↩︎
Vlaar APJ, Oczkowski S, de Bruin S, et al. “Transfusion Strategies in Non-bleeding Critically Ill Adults: A Clinical Practice Guideline From the European Society of Intensive Care Medicine.” Intensive Care Med. 2020;46(4):673-696. DOI: 10.1007/s00134-019-05884-8 ↩︎ ↩︎
Holst LB, Haase N, Wetterslev J, et al. “Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock.” N Engl J Med. 2014;371(15):1381-1391. DOI: 10.1056/NEJMoa1406617 ↩︎ ↩︎ ↩︎ ↩︎
Carson JL, Terrin ML, Noveck H, et al. “Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery.” N Engl J Med. 2011;365(26):2453-2462. DOI: 10.1056/NEJMoa1012452 ↩︎ ↩︎
Murphy GJ, Pike K, Rogers CA, et al. “Liberal or Restrictive Transfusion after Cardiac Surgery.” N Engl J Med. 2015;372(11):997-1008. DOI: 10.1056/NEJMoa1403612 ↩︎ ↩︎
Mazer CD, Whitlock RP, Fergusson DA, et al. “Restrictive or Liberal Red-Cell Transfusion for Cardiac Surgery.” N Engl J Med. 2017;377(22):2133-2144. DOI: 10.1056/NEJMoa1711818 ↩︎ ↩︎
Carson JL, Brooks MM, Abbott JD, et al. “Liberal or Restrictive Transfusion in High-Risk Patients with Acute Myocardial Infarction.” N Engl J Med. 2023;389(26):2446-2456. DOI: 10.1056/NEJMoa2307983 ↩︎ ↩︎ ↩︎ ↩︎
Villanueva C, Colomo A, Bosch A, et al. “Transfusion Strategies for Acute Upper Gastrointestinal Bleeding.” N Engl J Med. 2013;368(1):11-21. DOI: 10.1056/NEJMoa1211801 ↩︎ ↩︎
Robertson CS, Hannay HJ, Yamal JM, et al. “Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery after Traumatic Brain Injury: A Randomized Clinical Trial.” JAMA. 2014;312(1):36-47. DOI: 10.1001/jama.2014.6490 ↩︎ ↩︎
Napolitano LM, Kurek S, Luchette FA, et al. “Clinical Practice Guideline: Red Blood Cell Transfusion in Adult Trauma and Critical Care.” Crit Care Med. 2009;37(12):3124-3157. DOI: 10.1097/CCM.0b013e3181b39f1b ↩︎ ↩︎
Lacroix J, Hébert PC, Fergusson DA, et al. “Age of Transfused Blood in Critically Ill Adults.” N Engl J Med. 2015;372(15):1410-1418. DOI: 10.1056/NEJMoa1500704 ↩︎ ↩︎
Heddle NM, Cook RJ, Arnold DM, et al. “Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion.” N Engl J Med. 2016;375(20):1937-1945. DOI: 10.1056/NEJMoa1609014 ↩︎
Vamvakas EC, Blajchman MA. “Transfusion-Related Immunomodulation (TRIM): An Update.” Blood Rev. 2007;21(6):327-348. DOI: 10.1016/j.blre.2007.07.003 ↩︎